2022
DOI: 10.1111/cen3.12718
|View full text |Cite|
|
Sign up to set email alerts
|

The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders

Abstract: The launch of highly efficacious anti‐monoclonal antibody (mAb) drugs has profoundly changed the therapeutic strategy for multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD). However, the newly developed anti‐mAb drugs, especially those used in treating NMOSD, are quite expensive, resulting in a significant medical and economic burden. Early use of these drugs is expected to reduce the frequency of relapse and the accumulation of disability, preserve the quality of life of patients, and impr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 42 publications
0
1
0
Order By: Relevance
“…All instances of “anti‐monoclonal” should be changed to “monoclonal”, and “anti‐mAb” to “mAb”, in the affected articles 1–3 because the terms are not adequate.…”
mentioning
confidence: 99%
“…All instances of “anti‐monoclonal” should be changed to “monoclonal”, and “anti‐mAb” to “mAb”, in the affected articles 1–3 because the terms are not adequate.…”
mentioning
confidence: 99%